Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRTTSE:6034 -0.34%62 EV-to-EBITDA is 4.65 as of Sep. 15, 2026, which is 72% below its 10-year median of 16.36. GuruFocus rates TSE:6034 with a GF Score™ of 62/100 and a GF Value™ of 円607.97 (Fairly Valued). The stock has 4 warning signs investors should review. Among 520 Healthcare Providers & Services companies, MRT ranks better than 86.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MRT's enterprise value is 円1,950 Mil.
MRT's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円420 Mil. Therefore, MRT's EV-to-EBITDA for today is 4.65.
The historical rank and industry rank for MRT's EV-to-EBITDA or its related term are showing as below:
TSE:6034'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.08 Med: 16.36 Max: 93.12
Current: 4.64
During the past 12 years, the highest EV-to-EBITDA of MRT was 93.12. The lowest was -0.08. And the median was 16.36.
TSE:6034's EV-to-EBITDA is ranked better than 86.35% of 520
companies
in the Healthcare Providers & Services industry
Industry Median: 10.33
vs TSE:6034: 4.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-15), MRT's stock price is 円592.00.
MRT's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円14.180. Therefore, MRT's PE Ratio (TTM) for today is 41.75.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MRT's share price for today is 円592.00.
MRT's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円14.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MRT's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6034 vs HCA, THC, EHC: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, MRT's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MRT's EV-to-EBITDA falls into.
MRT's current Enterprise Value is 円1,950 Mil.
MRT's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円420 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRT (TSE:6034) has a EV-to-EBITDA of 4.65 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MRT. This is 72% below median its historical median of 16.36. According to the industry distribution chart, MRT ranks #71 out of 520 companies in the Healthcare Providers & Services industry, placing it in the top 13.7%.
Is MRT's EV-to-EBITDA too high?
MRT's current EV-to-EBITDA of 4.65 is 72% below median its 10-year median of 16.36. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.33. MRT's value of 4.65 is 55% below this industry median. Based on the distribution chart, MRT ranks #71 out of 520 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MRT has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MRT ranks #71 out of 520 companies for EV-to-EBITDA. This places MRT in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.33. MRT's value of 4.65 is 55% below this benchmark. While the company's 10-year median is 16.36 vs. the industry median of 10.33, MRT has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.33, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MRT's current EV-to-EBITDA of 4.65 is 55% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MRT. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MRT's current EV-to-EBITDA is 4.65, which is 72% below median its own 10-year median of 16.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円607.97, compared to a current price of 円592.00 — trading 2.6% below its estimated fair value. The current EV-to-EBITDA is 4.65, which is 72% below median its 10-year median of 16.36 and 55% below the Healthcare Providers & Services industry median of 10.33. MRT's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MRT (TSE:6034), the current EV-to-EBITDA is 4.65 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be undervalued.
The current stock price of 円592.00 is trading 2.6% below its estimated GF Value™ of 円607.97.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
EV-to-EBITDA: 4.65 (72% below median its 10-year median of 16.36)
GF Value™: 円607.97 vs. price of 円592.00 (2.6% below fair value)
Industry Position: 55% below the Healthcare Providers & Services median (#71 of 520)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
62GF Score
Get the complete analysis for TSE:6034
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
